Verona Pharma plc
VRNA
$65.46
$0.681.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 42.26M | 5.62M | -- | -- | -- |
| Total Other Revenue | 18.00K | -- | -- | -- | -- |
| Total Revenue | 42.28M | 5.62M | -- | -- | -- |
| Cost of Revenue | 2.58M | 543.00K | -- | -- | -- |
| Gross Profit | 39.70M | 5.08M | -- | -- | -- |
| SG&A Expenses | 149.75M | 119.64M | 97.79M | 61.20M | 50.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 193.31M | 156.93M | 128.87M | 73.19M | 66.47M |
| Operating Income | -151.03M | -151.30M | -128.87M | -73.19M | -66.47M |
| Income Before Tax | -163.13M | -151.76M | -123.69M | -62.37M | -53.90M |
| Income Tax Expenses | 10.29M | 1.97M | 1.76M | 1.06M | 474.00K |
| Earnings from Continuing Operations | -173.42 | -153.72 | -125.45 | -63.42 | -54.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.42M | -153.72M | -125.45M | -63.42M | -54.37M |
| EBIT | -151.03M | -151.30M | -128.87M | -73.19M | -66.47M |
| EBITDA | -149.97M | -150.30M | -127.97M | -72.41M | -65.79M |
| EPS Basic | -17.03 | -15.18 | -12.43 | -6.33 | -5.49 |
| Normalized Basic EPS | -1.22 | -1.14 | -0.93 | -0.49 | -0.43 |
| EPS Diluted | -17.29 | -15.45 | -12.70 | -6.60 | -5.76 |
| Normalized Diluted EPS | -1.22 | -1.14 | -0.93 | -0.49 | -0.43 |
| Average Basic Shares Outstanding | 326.14M | 323.50M | 321.79M | 320.07M | 317.04M |
| Average Diluted Shares Outstanding | 40.77M | 40.44M | 40.22M | 40.01M | 39.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |